{"denoms":[{"counts":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"122"}],"units":"Participants"}],"groups":[{"description":"F-627, 20 mg fixed dose pre-filled syringe, dosed Day 2 of each of 4 chemotherapy cycles.","id":"BG000","title":"F-627"},{"description":"Placebo, pre-filled syringe administered Day 2 of the first chemotherapy cycle; and F-627, 20 mg fixed dose pre-filled syringe administered Day 2 of each of the following 3 chemotherapy cycles.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.25","value":"50.8"},{"groupId":"BG001","spread":"9.00","value":"51.5"},{"groupId":"BG002","spread":"9.14","value":"51.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"122"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"120"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"121"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"68"}]}],"title":"Ukraine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"48"}]}],"title":"Russia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}],"title":"Hungary"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"52"}],"title":"Childbearing potential"},{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"65"}],"title":"Non-childbearing potential - Post-menopausal"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}],"title":"Non-childbearing potential - Surgically sterile"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Reproductive Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"5.36","value":"26.2"},{"groupId":"BG001","spread":"6.22","value":"27.4"},{"groupId":"BG002","spread":"5.65","value":"26.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"BMI (kg/m^2)","unitOfMeasure":"kg/m^2"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"73"}],"title":"Grade 0"},{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"49"}],"title":"Grade 1"}]}],"description":"The Eastern Cooperative Oncology Group (ECOG) performance status is a scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.\n\nGrade 0: fully active, able to carry on all pre-disease performance without restriction\n\nGrade 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work","paramType":"COUNT_OF_PARTICIPANTS","title":"Baseline ECOG","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"43"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"64"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"34"}],"title":"Stage III"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"24"}],"title":"Stage IV"}]}],"description":"Doctors combine the tumor, node, metastasis results and other factors specific to cancer to determine the stage of cancer for each person. Most types of cancer have four stages: stages I to IV. Stage IV is considered a worse outcome than Stage I.","paramType":"COUNT_OF_PARTICIPANTS","title":"Cancer Stage at Screening","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"572.21","value":"224.5"},{"groupId":"BG001","spread":"1337.99","value":"445.9"},{"groupId":"BG002","spread":"888.93","value":"294.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Days from Diagnosis","unitOfMeasure":"days"}]}